Sorafenat 200 MG Tablet contains Sorafenib 200mg, offering the same multi-kinase inhibition as Soranib in an alternative brand formulation, used for hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer.

How It Works: Sorafenib simultaneously inhibits Raf kinase (blocking MAPK pathway) and multiple VEGFR/PDGFR receptors (blocking angiogenesis), delivering dual anti-tumor activity through complementary mechanisms.

Common Uses: Unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and radioactive-iodine-refractory differentiated thyroid carcinoma.

Administration: Take twice daily on an empty stomach. Avoid high-fat meals within 1 hour before or 2 hours after dosing. Swallow whole with water.

Storage: Store below 25°C away from heat, moisture, and light. Keep out of reach of children.

Disclaimer: This product requires a valid prescription. Consult a licensed oncologist before use. This information is for educational purposes only.